Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for …

Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for …

K Takakura, S Koido, S Kan, K Yoshida… - Anticancer …, 2015 - ar.iiarjournals.org

Background/Aim: Treatment combining dendritic cells (DCs) pulsed with three types of major
histocompatibility complex (MHC) class I and II (DC/WT1-I/II)-restricted Wilms' tumor 1 (WT1)
peptides with chemotherapy may stabilize disease in pancreatic cancer patients. Materials

For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:

*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.

*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.

*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.

*Peptide Salt: TFA, Desalt, Acetate, HCl.

*Peptide Purity: From crude to ＞99.5%.

*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.

*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.

Quick Links:

Peptide Price
Peptide Modification
Peptide Library
Quote Request
Contact Us

Contact Information:

Eva He
eva@pepmic.com

Pepmic Co., Ltd
www.pepmic.com